Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 23 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
van den Bent MJ, Afra D, de Witte O, Hassel MB, Schraub S, Hoang-Xuan K, Malmström P-O, Collette L, Piérart M, Mirimanoff R, Karim ABMF, for the EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985-90. [Ref.ID 74824]
3. Cita con resumen
Peppercorn J M, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004;363:263-70. [Ref.ID 68829]
4. Cita con resumen
Anónimo. Three more EU orphan designations. Scrip 2003;2861:4. [Ref.ID 66209]
5. Cita con resumen
Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma T J, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJB. Effect of radiotherapy and other treatment-related factors on mid-term long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360:1361-8. [Ref.ID 63909]
6. Cita con resumen
Bradbury J. Tumour-tracking neural stem cells offer hope for glioma treatment. Lancet 2002;360:1226. [Ref.ID 63732]
7. Cita con resumen
8.
Muscat JE, Malkin MG, Thompson S, Shore RE, Stellman SD, McRee D, Neugut A I, Wynder EL. Handheld Cellular Telephone Use and Risk of Brain Cancer. JAMA 2001;284:3001-7. [Ref.ID 57161]
9.Tiene citas relacionadas
Trichopoulos D, Adami HO. Cellular telephones and brain tumors. N Engl J Med 2001;344:133-4. [Ref.ID 57100]
10.Tiene citas relacionadas
Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG, Fine HA, Black PM, Loeffler JS, Linet MS. Cellular-telephone use and brain tumors. N Engl J Med 2001;344:79-86. [Ref.ID 57099]
12.Tiene citas relacionadas Cita con resumen
Weinstein JN. Pharmacogenomics - teaching old drugs new tricks. N Engl J Med 2000;343:1408-9. [Ref.ID 53960]
13.Tiene citas relacionadas Cita con resumen
Esteller M, García-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4. [Ref.ID 53958]
14.
Carozza SE, Wrensch M, Milke R, Newman B, Olshan AF, Savitz DA, Yost M, Lee M. Occupation and adult gliomas. Am J Epidemiol 2000;152:838-46. [Ref.ID 53805]
15. Cita con resumen
Anónimo. Drugs of choice for cancer chemotherapy. Med Lett Drugs Ther 2000;42:83-92. [Ref.ID 52816]
16. Cita con resumen
Osoba D. Effects of temozolomide in malignant brain tumours. Lancet 2000;356:342. [Ref.ID 52184]
17. Cita con resumen
18. Cita con resumen
Anónimo. Cannabis potential in glioma and MS. Scrip 2000;2521:23. [Ref.ID 49860]
19. Cita con resumen
Anónimo. Temozolomide for refractory anaplastic astrocytoma. Med Lett Drugs Ther 1999;41:123-4. [Ref.ID 48542]
20.
Scott CB. Quality-adjusted survival analysis of malignant glioma patients. Control Clin Trial 1997;18:277-85. [Ref.ID 34224]
Seleccionar todas
 
 1 a 20 de 23 siguiente >>